These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mixed donor chimerism following stem cell transplantation for sickle cell disease. Shah NC; Rangarajan HG; Ngwube A; Shenoy S Curr Opin Hematol; 2023 Nov; 30(6):187-193. PubMed ID: 37694765 [TBL] [Abstract][Full Text] [Related]
5. Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Luck L; Zeng L; Hiti AL; Weinberg KI; Malik P Exp Hematol; 2004 May; 32(5):483-93. PubMed ID: 15145217 [TBL] [Abstract][Full Text] [Related]
6. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. Abraham A; Hsieh M; Eapen M; Fitzhugh C; Carreras J; Keesler D; Guilcher G; Kamani N; Walters MC; Boelens JJ; Tisdale J; Shenoy S; ; Biol Blood Marrow Transplant; 2017 Dec; 23(12):2178-2183. PubMed ID: 28882446 [TBL] [Abstract][Full Text] [Related]
7. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325 [TBL] [Abstract][Full Text] [Related]
9. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy. Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695 [TBL] [Abstract][Full Text] [Related]
10. Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease. El Hoss S; Cochet S; Godard A; Yan H; Dussiot M; Frati G; Boutonnat-Faucher B; Laurance S; Renaud O; Joseph L; Miccio A; Brousse V; Narla M; El Nemer W Haematologica; 2021 Oct; 106(10):2707-2719. PubMed ID: 32855279 [TBL] [Abstract][Full Text] [Related]
11. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586 [TBL] [Abstract][Full Text] [Related]
12. Ineffective erythropoiesis in sickle cell disease: new insights and future implications. El Nemer W; Godard A; El Hoss S Curr Opin Hematol; 2021 May; 28(3):171-176. PubMed ID: 33631786 [TBL] [Abstract][Full Text] [Related]
13. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Armistead PM; Mohseni M; Gerwin R; Walsh EC; Iravani M; Chahardouli B; Rostami S; Zhang W; Neuberg D; Rioux J; Ghavamzadeh A; Ritz J; Antin JH; Wu CJ Exp Hematol; 2008 Sep; 36(9):1205-15. PubMed ID: 18550258 [TBL] [Abstract][Full Text] [Related]
14. Arsenite exposure inhibits the erythroid differentiation of human hematopoietic progenitor CD34 Wan G; Medina S; Zhang H; Pan R; Zhou X; Bolt AM; Luo L; Burchiel SW; Liu KJ Sci Rep; 2021 Nov; 11(1):22121. PubMed ID: 34764389 [TBL] [Abstract][Full Text] [Related]
15. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564 [TBL] [Abstract][Full Text] [Related]
16. Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease. Han Y; Gao C; Liu Y; Zhang H; Wang S; Zhao H; Bao W; Guo X; Vinchi F; Lobo C; Shi P; Mendelson A; Luchsinger L; Zhong H; Yazdanbakhsh K; An X Blood; 2024 Mar; 143(11):1018-1031. PubMed ID: 38127913 [TBL] [Abstract][Full Text] [Related]
17. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Andreani M; Testi M; Gaziev J; Condello R; Bontadini A; Tazzari PL; Ricci F; De Felice L; Agostini F; Fraboni D; Ferrari G; Battarra M; Troiano M; Sodani P; Lucarelli G Haematologica; 2011 Jan; 96(1):128-33. PubMed ID: 20935000 [TBL] [Abstract][Full Text] [Related]
18. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040 [TBL] [Abstract][Full Text] [Related]
19. Beta-thalassemia and sickle cell disease in culture of early erythroid precursors: hemoglobin synthesis and ultrastructural study. Beuzard Y; Tulliez M; Testa U; Vainchenker W; Dubart A; Tsapis A; Galacteros F; Breton-Gorius J; Rosa J Blood Cells; 1981; 7(1):179-200. PubMed ID: 7187747 [TBL] [Abstract][Full Text] [Related]
20. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]